BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CODA Genomics, Inc. Obtains NIAID Funding For Synthetic Biology And Protein Expression Of DNA Mutant Gene Sets


10/19/2005 5:09:12 PM

IRVINE, Calif., Sept. 1 /PRNewswire/ -- CODA Genomics, Inc.(CODA), a synthetic biology and protein expression company, announced today that it has obtained NIAID funding for expansion of its synthetic gene assembly and protein expression technology to enable simultaneous formation of coordinated mutant sets of genes quickly, easily, and inexpensively. Such easy access to large libraries of directed mutations of natural proteins is critical to optimal protein-based drug discovery, rapid development of DNA vaccines, and exploration of protein structure/function relationships. The grant, in excess of $500,000, is a Small Business Technology Transfer (STTR) award between CODA and the University of California, Irvine (UCI). Dr. She-Pin Hung is the principal investigator (PI) for CODA, and Dr. Richard H. Lathrop is the PI for UCI.

CODA Genomics offers gene kits and services optimized to assemble DNA into single gene products that are guaranteed to express the desired protein. Current gene synthesis methods involve costly and time-consuming PCR, DNA sequencing, and sequence correction steps not necessary with CODA. CODA genes are optimized for correct self assembly, and also for characteristics that guarantee they express the desired protein at high levels in a biological expression system of choice, currently a difficult hurdle in protein drug discovery research. Most importantly, CODA's patented Translation Kinetics methods can create engineered DNA constructs that allow facile research on protein structure/function properties such as solubility, excretion, and folding.

Dr. Robert Molinari, CEO of CODA, comments, "CODA makes synthetic biology so robust that we can offer kits which guarantee that individual researchers in their own labs can assemble genes and express proteins. This saves time and expense. For large protein drug SAR (structure-activity relationship) studies, libraries of individual directed constructs can be made easily and quickly, with relative certainty that proteins will express properly. We are delighted the NIAID has chosen to fund the further development of this technology for large mutational studies."

CODA Genomics, Inc. was started in 2004 to commercialize the DNA assembly and protein expression optimization work from the laboratories of Drs. Richard Lathrop and G. Wesley Hatfield at the University of California, Irvine. The basic science was developed under a prestigious Information Technology Research (ITR) award to Drs. Lathrop and Hatfield from the National Science Foundation (NSF). In addition to DNA assembly thermodynamics, CODA optimizes codon usage preferences AND patented codon pair-wise combinations that control translational kinetics to generate high levels of the proper protein constructs. CODA's motto, "Synthetics Genes -- Guaranteed to Express." is put into practice with the company's CODExpress(TM) Gene Kits and Services. In addition, CODA offers collaborations for protein drug and production engineering based on large structure/activity studies of related proteins. These technologies allow researchers to assemble DNA constructs reliably, more quickly, less expensively, and on a scale never before possible.

CODA Genomics, Inc.

CONTACT: Dr. Robert Molinari, CEO of CODA Genomics, Inc., +1-650-917-9256,mole@codagenomics.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES